Close Menu

Well, knock GTO over with a feather: we never thought we'd see the day that "RNA interference" made it into a Wall Street Journal headline. This article reports on recent results from Alnylam Pharmaceuticals' human trial for its RNAi-based drug for respiratory syncytial virus. The story quotes Alnylam CEO John Maraganore as saying, "This is really the first moonwalk for RNAi therapeutics." Michael Jackson would be so proud.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan is to release rules governing some gene-edited food, according to NHK World.

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.